Synergy Pharmaceuticals posts a Q2 beat; announces spin-off of FV-100 assets

Synergy Pharmaceuticals (SGYP -0.2%) posts a solid Q2 beat as losses for the quarter were less than expected.

Cash and equivalents balance as of June 30 was $92.3M , up from $32.5M at the end of December, 2012.

Announces plans to spin off the part of its business working on a shingles treatment as a separate publicly traded company.

The newly formed subsidiary, ContraVir Pharmaceuticals, will hold the FV-100 assets in order to capitalize on significant growth opportunities and provide greater focus on the respective businesses and strategic priorities.

Comments (1)
  • Niksurfs
    , contributor
    Comments (96) | Send Message
    Does not get much better than this folks.... and the price is a steal
    9 Aug 2013, 02:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs